Royal College strongly disagrees with NICE draft for removal of dementia drugs
Mar 3, 2005 - 6:18:00 PM
|
|
|
"NICE suggests that only new prescriptions for anti-dementia drugs should be affected, and that patients already receiving treatment should be allowed to continue their therapy. This also provides an unjust and inequitable division in healthcare provision"
|
By Royal College of Psychiatrists,
[RxPG] The Royal College of Psychiatrists strongly disagrees with preliminary recommendations from NICE that the four drugs (cholinesterase inhibitors) currently licensed in the UK for use in Alzheimer's disease (donepezil, rivastigmine, galantamine and memantine) should not be used within the NHS, as they are not cost effective.
This advice directly contradicts previous NICE guidance in 2001, which made three of the drugs (donepezil, rivastigmine and galantamine) widely available to patients with Alzheimer's disease as a standard part of management within the NHS. Since that time, many tens of thousands of patients have received, and obtained benefit from, such medications. There have also been much wider benefits for patients and their carers, including the expansion of memory clinics and other services offering early diagnosis, advice and support for people with dementia and their carers.
The College supports NICE's conclusions that there is good evidence from clinical trials that they are effective, not only for improving memory, but for beneficial effects on behaviour and daily living tasks. However, economic analysis by NICE concluded that the cost of these drugs (around £2.50 per day) put them outside the range of cost-effectiveness that might be considered appropriate for the NHS, given the benefits they provide.
'Whilst these drugs do not provide a cure, or affect the underlying disease process, they can bring substantial benefit to many patients,- stated Professor Susan Benbow, chair of the Old Age Psychiatry Faculty.
'On average, drugs for Alzheimer's disease delay the decline associated with the illness by 6-9 months. This is a degree of benefit which clinicians, patients and carers value. The prescription of these drugs has been strongly supported by consumer groups such as the Alzheimer's Society. In our opinion, this degree of improvement in a devastating and progressive illness for which no other treatments are available is well worth the modest costs of the drugs-, continued Professor Benbow.
'Alternative treatments for people with dementia would include antipsychotic drugs for behavioural changes, a class of drugs known to be associated with significant and serious side-effects in this group of patients, unlike cholinesterase inhibitors which are generally very well tolerated.-
Many patients, carers and doctors have indicated that to obtain a 6-9 month period of stabilisation or improvement from a progressively relentless condition is well worth the price of £1000 per year, or £2.50 per day.
Anti-dementia drugs have been licensed in the UK since 1997, and prior to their widespread prescription throughout the NHS, which followed directly from the previous NICE guidance in January 2001, many families were forced to fund the cost of these drugs themselves through private prescriptions. The College is concerned that should the draft current NICE guidance be adopted, a similar situation would operate once again in England and Wales.
The economic models used to justify the withdrawal of these drugs from the NHS are, in our view, flawed. They rely on using QALY's, (Quality Adjusted Life Years), which make a variety of unknown and untested assumptions about how quality of life relates to dementia severity.
'These drugs are widely prescribed throughout the developed world, including countries in Europe, the US, Canada, Australia and New Zealand and have become more widely available in developing nations as well,- said Professor Benbow. 'If this preliminary guidance were to be applied, England and Wales would be the only developed nations which did not support prescription of these drugs within their healthcare system,- continued Professor Benbow.
'NICE suggests that only new prescriptions for anti-dementia drugs should be affected, and that patients already receiving treatment should be allowed to continue their therapy. This also provides an unjust and inequitable division in healthcare provision,- concluded Professor Benbow.
Advertise in this space for $10 per month.
Contact us today.
|
 |
|
Subscribe to UK Newsletter
|
|
|
|
Additional information about the news article
|
The College's Faculty of Old Age Psychiatry will be reviewing the draft NICE guidance and will be issuing a detailed response in the near future
|
|
Feedback
|
For any corrections of factual information, to contact the editors or to send
any medical news or health news press releases, use
feedback form
|
Top of Page
|
